

v1: 14 November 2024

## Commentary

# A Harmless Avian Vaccine Virus Could Be Developed into an Off-the-Shelf “Antibiotic” for Viruses

Preprinted: 29 October 2024

Peer-approved: 14 November 2024

© The Author(s) 2024. This is an Open Access article under the CC BY 4.0 license.

Qeios, Vol. 6 (2024)  
ISSN: 2632-3834

Tibor Bakacs<sup>1</sup>, Konstantin Chumakov<sup>2</sup>

1. Alfréd Rényi Institute of Mathematics, Budapest, Hungary; 2. Department of Microbiology, Immunology, and Tropical Medicine, George Washington University, United States

A repurposed apathogenic double-stranded (ds) RNA vaccine virus, the infectious bursal disease virus (IBDV), significantly upregulates the expressions of type I interferon (IFN) genes. IBDV superinfection therapy (SIT) has been proven to be safe and effective against hepatitis A, B, and C viruses (HAV, HBV, HCV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and herpes zoster virus (HZV). IBDV might be used to control most virus infections before adaptive immunity develops. The safety and efficacy of a reverse-engineered new IBDV viral drug candidate, strain R903/78, could be reconfirmed in herpes zoster patients in a short-term Phase I/II study. With an off-the-shelf, stockpiled R903/78 drug, many millions of deaths and a repeat of the US\$12 trillion the world spent on COVID-19 could be mitigated.

**Corresponding author:** Tibor Bakacs, [tiborbakacs@gmail.com](mailto:tiborbakacs@gmail.com)

Holmes et al. predicted that during the next fifty years, an important area for research in virology will be the competition of viruses. Viral interference should enable the development of better strategies for virus control<sup>[1]</sup>. There is no need to wait fifty years because the idea of fighting fire with fire, i.e., using non-pathogenic viruses to control unrelated infections, has already been translated into a host-directed antiviral therapy and successfully tested against five different families of viruses<sup>[2]</sup>.

The objective of this article, therefore, is to argue that the infectious bursal disease virus (IBDV) drug candidate, strain R903/78, could be developed into an off-the-shelf stockpiled post-infection antiviral drug with modest funding within a relatively short time. In the era of large-scale vaccine hesitancy and skepticism, a broad-spectrum oral affordable antiviral drug could complement vaccination and improve pandemic preparedness. Actually, vaccination alone will not be sufficient to control future pandemics caused by rapidly evolving RNA viruses. Let alone that the frequency of zoonotic diseases is increasing because people exert pressures on nature, particularly via the huge livestock industry<sup>[3][4][5][6]</sup>.

Zoonotic diseases are some of the most common and/or most dangerous diseases, including influenza, rabies, Lyme disease, Lentiviral immunodeficiency

viruses, Ebola, SARS, and plague. The ability of zoonotic pathogens to transmit to humans is behind the concept of One Health, postulating the interdependence between animal and human health and aiming at improving preparedness for emerging infectious diseases. Probably the greatest known zoonotic risk to human health worldwide is presented by pandemic influenza. In the past 106 years, there have already been four influenza pandemics, and experts predict that another influenza pandemic is inevitable. In a few months, a pandemic flu strain could infect around 30% of the global population and could result in 200 million deaths during its first wave<sup>[3][7]</sup>.

The primary carriers of influenza are poultry and pigs. Close to 20 billion chickens and 1 billion pigs are produced annually worldwide, which are the primary drivers of influenza pandemic risk to humans. The low-pathogenic strain of wild birds can be transformed into a highly pathogenic form that can cause mass mortality in poultry and, potentially, in people. Pigs serve as the genetic engineering laboratory of nature. They are ideal mixing vessels, combining existing strains of influenza from birds or other animals, and transmitting them to humans, amplifying the pandemic risk. Livestock, therefore, is one of our 'blind spots in biodefense'<sup>[4]</sup>. After COVID-19, we no longer have to imagine what an influenza pandemic would look like<sup>[5]</sup>.

The fighting fire with fire idea has already been tested during the 1960s and 1970s. Large-scale clinical studies involving more than 60,000 individuals demonstrated that existing live vaccines can indeed protect against unrelated infections<sup>[8]</sup>. The oral poliovirus vaccine (OPV) reduced the morbidity of influenza virus infection 3.8-fold. OPV vaccination also had an accelerating healing effect on genital herpes simplex virus infections. Based on these pivotal early studies, Chumakov et al. proposed that live vaccines may temporarily protect against COVID-19<sup>[9]</sup>. This prediction was confirmed by Yagovkina et al., who demonstrated that a single dose of bivalent OPV significantly reduced the number of COVID-19 cases in 1115 healthy volunteers (aged 18 to 65). This is consistent with the hypothesis that live attenuated vaccines can induce non-specific protection against off-target infections<sup>[10][11]</sup>.

Clinical observations of natural viral interference paved the way for viral therapies. Hepatitis B virus (HBV) infection is often terminated after accidental coinfection by hepatitis C virus (HCV). HCV dominance over HBV could, in turn, be terminated following the eradication of HCV by direct-acting antiviral (DAA) therapy. Consequently, HBV infection is often reactivated. When both interfering viruses are pathogenic, the disease (e.g., hepatitis) persists. Apathogenic viruses could, however, be exploited to control acute or chronic viral diseases. Such intentional coinfection is the *superinfection therapy* (SIT)<sup>[12]</sup>.

The IBDV drug candidate of SIT is orally administered to patients suffering from acute or chronic viral diseases. IBDV delivers its double-stranded (ds) RNA cargo into host cells, where the dsRNA activates the native antiviral interferon (IFN) gene defense system via Toll-like receptors (TLRs). IBDV strongly induces IFN- $\beta$  and IFN- $\lambda$ , while IFN- $\gamma$  is not induced. As IBDV did not lyse several mammalian cell lines, inflammation and antiviral efficacy are separated. In such a way, the therapeutic window is opened up such that IBDV maximizes antiviral efficacy with only minimal side effects<sup>[13]</sup>.

IBDV is not known to infect human beings naturally. Consistent with this, IBDV R903/78 replication in mice could not be confirmed from multiple oral delivery experiments. In the presence of a rapid neutralizing antibody response, a wide

range of IBDV R903/78 tissue distribution indicated genome accumulation rather than viral replication<sup>[14]</sup>. This observation is consistent with clinical experience. IBDV superinfection therapy was effective in several decompensated chronic hepatitis patients, showing striking clinical improvement without side effects when large doses (up to a cumulative dose of  $3 \times 10^9$  infective particles) of the viral preparation were administered continuously over a long period to ensure the maintenance of 'artificial viremia' by IBDV. This is, in turn, consistent with the observation that repeated administration of Newcastle disease virus (NDV) remained effective in cancer patients despite the presence of neutralizing antibodies<sup>[12][15]</sup>. Importantly, IBDV treatment never induced an excessive release of pro-inflammatory cytokines, even though chronic HBV or HCV patients with decompensated liver disease had high-level viremia, which is a key driver of the cytokine storm<sup>[13]</sup>.

IBDV has been proven to be safe and effective in marmoset monkeys and more than 50 patients against hepatitis A, B, and C viruses (HAV, HBV, HCV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and herpes zoster virus (HZV)<sup>[16][17][18][19][20][21][22][13]</sup>. The immunostimulatory power of IBDV is obvious to the naked eye, when a severe herpes zoster ophthalmicus (HZO) infection of the first author of this paper was healed within a few days<sup>[21]</sup>.

## **The Safety and Efficacy of Reverse Engineered IBDV R903/78 Drug Candidate Could Be Reconfirmed in Herpes Zoster Patients**

Attenuated IBDV has been used safely for over 60 years in IBDV mass vaccination programs in the poultry industry. Although attenuated avian vaccine viruses carry only a very low risk of mutation-associated zoonosis, it is a legitimate concern for the regulatory authorities. Therefore, an IBDV vaccine virus was recreated by reverse genetics technology as an artificial virus, the R903/78 drug candidate<sup>[14]</sup>. This virus can be produced without labor-intensive re-plating in the event of the appearance of contaminating quasi-species. Experts of the US National Institutes of Health-sponsored ACTIV public-private partnership concluded that the IBDV strain R903/78 shows merit as a potential treatment for COVID-19.

The crusting time of vesicles following a standard of care acyclovir monotherapy with acyclovir plus an add-on R903/78 combination therapy could be compared during a short-term (one week) Phase I/II study in herpes zoster patients as described in<sup>[22]</sup>. The long-term safety and efficacy of the R903/78 drug candidate could be evaluated in virally suppressed HBeAg-negative chronic hepatitis B (CHB) patients as described in<sup>[20]</sup>. Those CHB patients who could not achieve functional cure during R903/78 monotherapy should be treated by sequential ultra-low dose ipilimumab plus nivolumab therapy as described in<sup>[20][13]</sup>.

Over the last fifty years, the paradigm-changing idea of using non-pathogenic viruses to control viral diseases was translated into experimental antiviral therapies. Notwithstanding, the therapeutic exploitation of viral competition has still been unfairly overlooked when another influenza pandemic is inevitable. The avian H5N1 influenza virus is currently spreading through dairy cows and other mammals with transmission to humans, demonstrating that high-density commercial farming of animals poses a major pandemic threat<sup>[23]</sup>. As the most

high-risk pandemic threat is the flu virus, it should be prioritized for resources. The development of the R903/78 drug candidate into an off-the-shelf stockpiled broad-spectrum post-infection antiviral drug could mitigate future pandemic deaths. This way, a repeat of the US\$12 trillion the world spent on COVID-19 could also be reduced<sup>[24]</sup>.

## Statements and Declarations

### *Funding*

None.

### *Conflicts of Interest*

Tibor Bakacs declares stock/stock options from HepC Inc. and he is also a shareholder of HepC Inc. Konstantin Chumakov has nothing to declare.

### *Ethics*

Ethical review and approval were not required for this commentary article. However, the authors affirm that all cited studies involving animal experimentation adhered to institutional and national guidelines. Furthermore, the authors affirm that all cited studies involving human participants were conducted in accordance with the Declaration of Helsinki, and appropriate institutional review board approval and informed consent were obtained where applicable, as detailed in the original publications. Any future clinical studies proposed herein will require review and approval by an appropriate institutional review board or ethics committee, and informed consent will be obtained from all participants.

### *Author Contributions*

Conceptualization: T.B., K.C.; Writing – original draft preparation: T.B.; Writing – review and editing: T.B., K.C. Both authors contributed to the article and approved the submitted version.

## References

1. <sup>△</sup>Holmes EC, Krammer F, Goodrum FD (2024). "Virology 2014-The next fifty years." *Cell*. **187**:5128–5145. doi:10.1016/j.cell.2024.07.025.
2. <sup>△</sup>Bakacs T, Chumakov K, Safadi R, Kovesdi I (2022). "Editorial: Fighting fire with fire: Using non-pathogenic viruses to control unrelated infections." *Front Immunol*. **13**:1046851. doi:10.3389/fimmu.2022.1046851.
3. <sup>△</sup><sub>a</sub><sup>△</sup><sub>b</sub>Linder A, Nadzam B, Jamieson D, Stilt K, McCarthy V (2024). *Animal Markets and Zoonotic Disease Risk: A Global Synthesis of a 15 Country Study*. Harvard Law School:163.
4. <sup>△</sup><sub>a</sub><sup>△</sup><sub>b</sub>Linder A, Jamieson D (2023). "Blind spots in biodefense." *Science*. **379**:621–621. doi:10.1126/science.adg9237.
5. <sup>△</sup><sub>a</sub><sup>△</sup><sub>b</sub>Linder A, Green C, Nadzam B, Jamieson D, Stilt K (2023). *I: Animal Markets and Zoonotic Disease in the United States*. Harvard Law School:170.
6. <sup>△</sup>Morens DM, Daszak P, Markel H, Taubenberger JK (2020). "Pandemic COVID-19 Joins History's Pandemic Legion." *mBio*. **11**. doi:10.1128/mbio.00812-20.

7. <sup>^</sup>Gatherer D (2009). "The 2009 H1N1 influenza outbreak in its historical context." *J Clin Virol.* 45:174–178. doi:[10.1016/j.jcv.2009.06.004](https://doi.org/10.1016/j.jcv.2009.06.004).
8. <sup>^</sup>Chumakov MP, Voroshilova MK, Antsupova AS, Boiko VM, Blinova MI, Priimiagi LS, Rodin VI, Seibil VB, Siniak KM, Smorodintsev AA, et al. (1992). "Live enterovirus vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases." *Zh Mikrobiol Epidemiol Immunobiol.*37–40.
9. <sup>^</sup>Chumakov K, Benn CS, Aaby P, Kottiril S, Gallo R (2020). "Can existing live vaccines prevent COVID-19?" *Science.* 368:1187–1188. doi:[10.1126/science.abc4262](https://doi.org/10.1126/science.abc4262).
10. <sup>^</sup>Chumakov K, Avidan MS, Benn CS, Bertozzi SM, Blatt L, Chang AY, Jamison DT, Khader SA, Kottiril S, Netea MG, Sparrow A, Gallo RC (2021). "Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics." *Proceedings of the National Academy of Sciences.* 118:e2101718118. doi:[10.1073/pnas.2101718118](https://doi.org/10.1073/pnas.2101718118).
11. <sup>^</sup>Yagovkina NV, Zheleznov LM, Subbotina KA, Tsaan AA, Kozlovskaya LI, Gordeychuk IV, Korduban AK, Ivin YY, Kovpak AA, Pinaeva AN, Shishova AA, Shustova E Y, Khapchaev YK, Karganova GG, Siniugina AA, Pomaskina TV, Erovichenkov AA, Chumakov K, Ishmukhametov AA (2022). "Vaccination With Oral Polio Vaccine Reduces COVID-19 Incidence." *Front Immunol.* 13. doi:[10.3389/fimmu.2022.907341](https://doi.org/10.3389/fimmu.2022.907341).
12. <sup>a, b</sup>Bakacs T, Safadi R, Kovesdi I (2018). "Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs." *Hepatology Med Policy.* 3: 2. doi:[10.1186/s41124-017-0028-x](https://doi.org/10.1186/s41124-017-0028-x).
13. <sup>a, b, c</sup>Bakacs T, Fehér LZ, Puskás LG (2024). "Sting Pathway Activation by Orally Administered Attenuated dsRNA Vaccine Virus for Therapy of Viral Diseases." *Qeios.* doi:[10.32388/S7SMJS.2](https://doi.org/10.32388/S7SMJS.2).
14. <sup>a, b</sup>Hornyak A, Lipinski KS, Bakonyi T, Forgach P, Horvath E, Farsang A, Hedley SJ, Palya V, Bakacs T, Kovesdi I (2015). "Effective multiple oral administration of reverse genetics engineered infectious bursal disease virus in mice in the presence of neutralizing antibodies." *J Gene Med.* 17:116–131. doi:[10.1002/jgm.2830](https://doi.org/10.1002/jgm.2830).
15. <sup>^</sup>Csatary LK, Moss RW, Beuth J, Torocsik B, Szeberenyi J, Bakacs T (1999). "Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H)." *Anticancer Res.* 19:635–638.
16. <sup>^</sup>Csatary LK, Kasza L, Massey RJ (1984). "Interference between human hepatitis A virus and an attenuated apathogenic avian virus." *Acta Microbiol Hung.* 31:153–158.
17. <sup>^</sup>Csatary LK, Telegdy L, Gergely P, Bodey B, Bakacs T (1998). "Preliminary report of a controlled trial of MTH-68/B virus vaccine treatment in acute B and C hepatitis: a phase II study." *Anticancer Res.* 18:1279–1282.
18. <sup>^</sup>Csatary LK, Schnabel R, Bakacs T (1999). "Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine." *Anticancer Res.* 19:629–633.
19. <sup>^</sup>Bakacs T, Volker S, Kovesdi I (2022). "An Orally Administered Nonpathogenic Attenuated Vaccine Virus Can Be Used to Control SARS-CoV-2 Infection: A Complementary Plan B to COVID-19 Vaccination." *Cureus.* 14:e28467. doi:[10.7759/cureus.28467](https://doi.org/10.7759/cureus.28467).
20. <sup>a, b, c</sup>Bakacs T, Safadi R, Puskás LG, Fehér LZ, Kovesdi I (2022). "Sequential Combination of a Strong Interferon Inducer Viral Vector With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus Infections: Technical Report Proposing a New Modality." *Cureus.* 14:e22750. doi:[10.7759/cureus.22750](https://doi.org/10.7759/cureus.22750).

21. <sup>a</sup>, <sup>b</sup>Bakacs T (2021). "Healing of Severe Herpes Zoster Ophthalmicus Within a Few Days: An Autobiographical Case Report." *Cureus*. **13**:e20303. doi:[10.7759/cureus.20303](https://doi.org/10.7759/cureus.20303).
22. <sup>a</sup>, <sup>b</sup>Bakacs T, Sandig V, Kovesdi I (2023). "Combination Therapy for the Treatment of Shingles with an Immunostimulatory Vaccine Virus and Acyclovir." *Pharmaceuticals*. **16**:226.
23. <sup>^</sup>Alwine J, Goodrum F, Banfield B, Bloom D, Britt William J, Broadbent Andrew J, Campos Samuel K, Casadevall A, Chan Gary C, Cliffe Anna R, Dermody T, Duprex P, Enquist Lynn W, Frueh K, Geballe Adam P, Gaglia M, Goldstein S, Greninger Alexander L, Gronvall Gigi K, Jung Jae U, Kamil Jeremy P, Lakdawala S, Liu S-L, Luftig M, Moore John P, Moscona A, Neuman Benjamin W, Nikolich Janko Ž, O'Connor C, Pekosz A, Permar S, Pfeiffer J, Purdy J, Rasmussen A, Semler B, Smith Gregory A, Stein David A, Van Doorslaer K, Weller Sandra K, Whelan Sean PJ, Yurochko A (2024). "The harms of promoting the lab leak hypothesis for SARS-CoV-2 origins without evidence." *J Virol*. **98**:e01240-01224. doi:[10.1128/jvi.01240-24](https://doi.org/10.1128/jvi.01240-24).
24. <sup>^</sup>Berkley S (2022). "Even after COVID, the world's vaccine strategy is failing." *Nature*. **612**:377. doi:[10.1038/d41586-022-04423-8](https://doi.org/10.1038/d41586-022-04423-8).

## Declarations

**Funding:** No specific funding was received for this work.

**Potential competing interests:** No potential competing interests to declare.